Thus, an immunoscore, which quantifies cytotoxic T cells in the TME by combining CD3+ and CD8+ T cell densities, was incorporated into the 2020 ESMO Clinical Practice Guidelines for localized colon cancer to refine prognosis in conjunction with TNM staging [24]. Here, CD8A is linked to malignant colon neoplasm.